Zobrazeno 1 - 10
of 113
pro vyhledávání: '"George Ansstas"'
Autor:
Jordan Phillipps, George Nassief, Renee Morecroft, Tolulope Adeyelu, Andrew Elliott, Farah Abdulla, Ari Vanderwalde, Soo Park, Omar Butt, Alice Zhou, George Ansstas
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-7 (2024)
Abstract Modern advancements in targeted therapy and immunotherapy have significantly improved survival outcomes for advanced melanoma; however, there remains a need for novel approaches to overcome disease progression and treatment resistance. In re
Externí odkaz:
https://doaj.org/article/f055827c4c6d4ee798e7772fa7846f0a
Publikováno v:
JAAD Case Reports, Vol 48, Iss , Pp 59-61 (2024)
Externí odkaz:
https://doaj.org/article/53a0d1f37ebc46a79297a6765deed636
Autor:
Favour A. Akinjiyan, George Nassief, Jordan Phillipps, Tolulope Adeyelu, Andrew Elliott, Farah Abdulla, Alice Y. Zhou, George Souroullas, Kevin B. Kim, Ari Vanderwalde, Soo J. Park, George Ansstas
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract ARID genes encode subunits of SWI/SNF chromatin remodeling complexes and are frequently mutated in human cancers. We investigated the correlation between ARID mutations, molecular features, and clinical outcomes in melanoma patients. Cutaneo
Externí odkaz:
https://doaj.org/article/12330a2b365b4ae9b93fc739ef7b1daa
Autor:
Renee Morecroft, Jordan Phillipps, Alice Zhou, Omar Butt, Karam Khaddour, Tanner Johanns, George Ansstas
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Immunotherapy is the first-line option for treating advanced cutaneous squamous cell carcinoma (cSCC). However, up to half of patients experience no benefit and treatment resistance, warranting newer therapeutic approaches. Combinatory approaches, in
Externí odkaz:
https://doaj.org/article/f2b84d8281f7481ab6a940c93f2daab0
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 18, p 9848 (2024)
Malignant melanoma outcomes have drastically changed in recent years due to the introduction of immune checkpoint inhibitors (ICIs). However, many patients still experience intolerable side effects, therapy resistance, and disease progression on ICI
Externí odkaz:
https://doaj.org/article/5cb6243386f849bdb3ce0f4cdb30efb0
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 916 (2024)
Skin cancer prognosis has greatly improved recently due to the introduction of immune checkpoint inhibitors (ICIs). However, many patients with advanced skin cancer still experience immunotherapy resistance and disease progression during ICI treatmen
Externí odkaz:
https://doaj.org/article/f0c599bb67e642859e071d3c5e64c282
553 Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b622b3313e8d4199bbf2ffb82815bee8
Autor:
Ari VanderWalde, Andrew Elliott, George Ansstas, Soo Park, Kevin Kim, George P Souroullas, Tolulope Adeyelu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e28a6a361c17496ba770a547c2a7f6d5
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Oligometastatic progression represents a unique manifestation of tumor immune-escape that can lead to disease progression during treatment with immune checkpoint inhibitor (ICI). The diagnosis and further optimal management of oligometastatic progres
Externí odkaz:
https://doaj.org/article/170e45a8bf904e4b84ca608b441899ff
Autor:
Leonid Shmuylovich, MD, PhD, Aubriana M. McEvoy, MD, MS, Ryan C. Fields, MD, Leonel Hernandez-Aya, MD, George Ansstas, MD, David Y. Chen, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 29, Iss , Pp 131-133 (2022)
Externí odkaz:
https://doaj.org/article/d8801dba21884d899ff85dcdd8d0b159